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against thromboembolism. This possibly
contributes to the difference in the inci-
dence of thromboembolic complications
between the two groups.
This study has not shown compelling
evidence in support of its claim. It probably
emphasizes the importance of prophylaxis
for thromboembolism in high-risk patients
undergoing OPCAB.
D. L. Ngaage, MB, BS, FWACS, FRCS
Department of Cardiothoracic Surgery
Yorkshire Heart Center
Leeds General Infirmary
Great George Street
Leeds LS1 3EX, United Kingdom
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Reply to the Editor:
Dr Ngaage brought up interesting remarks
that we would like to address. The two
cohorts of patients that we compared were
not exactly selected. The beating heart cor-
onary artery bypass (OPCAB) cohort in-
cluded 500 consecutive cases of coronary
artery revascularization representing 95%
of all traditiional coronary artery bypass
graft (CABG) cases done by our group
during that period (98% for 1999 and
2000). Only very hemodynamically unsta-
ble patients requiring high doses of inotro-
pic drugs or patients having specific technical
difficulties, such as deep intramyocardial in-
ternal thoracic artery or tight posterior adhe-
sions precluding safe dissection, were re-
jected for the OPCAB approach. The cohort
of patients in whom cardiopulmonary bypass
(CPB) was used comprised all patients oper-
ated on from April 1998 through March 2000
(corresponding to 2 “clerical years” for the
archive department) who underwent CABG
on CPB with no other associated procedures.
No cases were excluded. Therefore, these
two cohorts were obviously not matched.
However, they were not “selected” or “cho-
sen” either. Furthermore, as seen in Tables 1
and 2, they were both comparable in terms of
preoperative risk factors and surgical data.
Preoperative intra-aortic balloon pumping
was used more often in the OPCAB group,
but postoperative balloon pumping use was
more frequent in the CPB groups. Globally,
the perioperative use of balloon pumps was
comparable (7.8% vs 6.4%, P .33) for both
groups.
We are aware that most of the throm-
boembolic complications occurring postop-
eratively are not clinically detected. Be-
cause this study was retrospective, we were
limited in clinical manifestations of venous
thromboembolic disease as they were re-
ported in the patients’ charts. These are the
manifestations that are important and mat-
ter for both the patients and the clinicians.
For clerical purposes, events were similarly
reported for both groups. For a vast major-
ity (95%) of patients, the saphenous vein
was also harvested and used as a vascular
conduit, regardless of the technique used,
which consequently should not be taken as
a heterogeneous issue. In our practice at the
Montreal Heart Institute, thromboembolic
prophylaxis has never been routinely used
for either on-pump or off-pump cases. Em-
phasis was put on early mobilization and
physiotherapist care. No patients in either
cohort reported in the current study re-
ceived any prophylaxis against thrombo-
embolism. Whether this was good or
TABLE 2. Surgical data for OPCAB and CPB patients
OPCAB CPB
P
value
Grafts/patient 3.08 0.89 2.91/0.67 .006
Ischemic time
(min)
30 11 43 16 .001
Grafts/territory 1.16 0.26 1.14 0.34 .25
Postop IABP
(%)
0.8 2.9 .01
TABLE 1. Demographics and preoperative risk factors for OPCAB and CPB
patients
OPCAB CPB
P
value
Age (y) 64 10 63 9 NS
Sex ratio 3.54 3.71 NS
Diabetes (%) 25 21 NS
HBP (%) 47 54 NS
Tobacco (%) 32 29 NS
COPD (%) 11 9 NS
Redo (%) 7 7 NS
MI 30 days (%) 16 18 NS
Previous CVA (%) 9 7.3 NS
Carotid bruit (%) 16 13 NS
PVD (%) 19 14 NS
Unstable angina (%) 68 72 .05
LVEF (%) 54 13 54 15 NS
LVEF 40% (%) 14 17 NS
Left main 50% (%) 30 28 NS
Preoperative IABP
(%)
7 3.5 .05
Territory involved 2.7 0.6 2.6 0.54 NS
HBP, High blood pressure; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction;
CVA, cerebrovascular accident; PVD, peripheral vascular disease; LVEF, left ventricular ejection
fraction; IABP, intra-aortic balloon pump; NS, not significant.
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wrong could be debated, but one fact re-
mains: thromboembolic complications
have been an unusual cause of early post-
operative morbidity or mortality in our ex-
perience, as shown by the 0.5% incidence
that we reported in the CPB group. In an
article by Clagett and associates,1 there was
no mention of specific prophylaxis for car-
diac surgery. Nevertheless, we do agree on
the importance of prophylaxis in OPCAB
surgery. So far, we have not found any
negative side effects associated with it.
Since we started applying this policy to all
our OPCAB patients, we have seen an ob-
vious decrease in the incidence of throm-
boembolism without any increased bleed-
ing complications or transfusion needs.
Raymond Cartier, MDa
Danielle Robitailleb
Department of Cardiac Surgerya
Department of Hematologyb
Montreal Heart Institute
Montreal, Quebec H1T 1CS, Canada
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Single fiber skeletal muscle
transplantation or purified myoblast
engraftment?
To the Editor:
We read with interest the article of Suzuki
and colleagues,1 “Single Fibers of Skeletal
Muscle as a Novel Graft for Cell Trans-
plantation to the Heart.” They investigated
the feasibility of single skeletal muscle fi-
bers as a vehicle to deliver putative myo-
blasts-myotubes into the myocardium in rat
models. They further demonstrated the im-
provement of cardiac function and histo-
logic evidence of cell proliferation and sur-
vival after single muscle fiber engraftment
into the infarcted myocardium.
This is an important study in skeletal
myoblast transplantation for cardiac repair,
because mechanisms for improvement of
cardiac function after myoblast transplan-
tation have not been clearly identified. Al-
though clinical application of myoblast
transplantation for cardiac repair is already
being assessed in phase I human studies,2
many questions regarding the optimization
of the transplantation conditions and pro-
cedure remain unanswered.3
It appears logical to consider that the
number of myoblasts that repopulate the
infarcted myocardium must be important.
In all other experimental studies, a signif-
icantly larger number of cells were im-
planted. Improvement in myocardial func-
tion has been directly related to the number
of cells injected which in rodents is 3 to 6
million cells and large animals as many as
1 billion cells. Suzuki and colleagues1 in
their study used only 4 single fibers per
heart for injection. According to their find-
ings, each single fiber retained 20 myo-
blasts, as assessed by immunostaining for
M-cadherin, meaning that only 80 myo-
blasts were transplanted. Therefore myo-
blasts had to undergo extensive prolifera-
tion after transplantation to achieve an
optimum cell count for beneficial effect. It
seems unreasonable to expect that as few as
4 single skeletal fibers (80 myoblasts)
would bring about significant improvement
of heart function. From the figures shown,
the extent of repopulation of the myocar-
dium with cells is unclear, and only a few
myotubules have been formed, which
would be unlikely to improve cardiac func-
tion significantly in a severely damaged
heart.
The disadvantages pointed out by Su-
zuki and colleagues1 of using expanded
cultures of myoblast as opposed to single
fibers are only theoretic. The problem of
embolism from myoblast injection has
never been reported, even when they are in-
jected intra-arterially or intracoronarily.4,5
Similarly, in clinical perspective, delaying an
elective operation on a patient in stable con-
dition to expand the myoblast number is not
a major problem. Our experience and the
current literature do not indicate that repeated
passaging of myoblasts leads to significant
deterioration or problems.
One of the important findings in this
article is the development of multinucleate
branching myotubes. Because the grafted
myofibers were postmitotic, it was deduced
that skeletal myoblasts were the source of
the newly formed fibers. In a porcine model
of chronic ischemia with transient immu-
nosuppression, we implanted lacZ-positive
human myoblasts of greater than 95% pu-
rity. At 6 weeks we demonstrated similar
formation of new branching centrally lo-
cated multinucleate myotubules. Most of
the nuclei stained positively for -galacto-
sidase (Figure 1). We believe that after
myoblast transplantation neomyogenesis
results in fibers with phenotypic features
similar to skeletal and cardiac muscles and
that this is the mechanism of improvement
in cardiac function.
Eugene K. W. Sim, FRCS
Husnain K. Haider, PhD
Peter K. Law, PhD
National University of Singapore
Singapore
Figure 1. Xenotransplanted human skeletal myoblasts carrying lacZ reporter gene with
nuclear localization signal in porcine heart model of chronic ischemia at 6 weeks after
transplantation. Tissue sections were stained with X-gal according to standard protocol.
Arrows represent donor human myoblast nuclei.
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